371 related articles for article (PubMed ID: 23320019)
1. Modulation of immunity by antiangiogenic molecules in cancer.
Terme M; Colussi O; Marcheteau E; Tanchot C; Tartour E; Taieb J
Clin Dev Immunol; 2012; 2012():492920. PubMed ID: 23320019
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
Tartour E; Pere H; Maillere B; Terme M; Merillon N; Taieb J; Sandoval F; Quintin-Colonna F; Lacerda K; Karadimou A; Badoual C; Tedgui A; Fridman WH; Oudard S
Cancer Metastasis Rev; 2011 Mar; 30(1):83-95. PubMed ID: 21249423
[TBL] [Abstract][Full Text] [Related]
3. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.
Welti J; Loges S; Dimmeler S; Carmeliet P
J Clin Invest; 2013 Aug; 123(8):3190-200. PubMed ID: 23908119
[TBL] [Abstract][Full Text] [Related]
4. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
5. Targeting VEGF/VEGFR to Modulate Antitumor Immunity.
Yang J; Yan J; Liu B
Front Immunol; 2018; 9():978. PubMed ID: 29774034
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis: a target for cancer therapy.
Tortora G; Melisi D; Ciardiello F
Curr Pharm Des; 2004; 10(1):11-26. PubMed ID: 14754402
[TBL] [Abstract][Full Text] [Related]
7. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
8. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
9. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
10. Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment.
Bourhis M; Palle J; Galy-Fauroux I; Terme M
Front Immunol; 2021; 12():616837. PubMed ID: 33854498
[TBL] [Abstract][Full Text] [Related]
11. Escape mechanisms from antiangiogenic therapy: an immune cell's perspective.
Rivera L; Pandika M; Bergers G
Adv Exp Med Biol; 2014; 772():83-99. PubMed ID: 24272355
[TBL] [Abstract][Full Text] [Related]
12. Synopsis of angiogenesis inhibitors in oncology.
Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
[TBL] [Abstract][Full Text] [Related]
13. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
14. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
15. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
Hegde PS; Wallin JJ; Mancao C
Semin Cancer Biol; 2018 Oct; 52(Pt 2):117-124. PubMed ID: 29229461
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic agents and targets: A perspective.
Teicher BA
Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
18. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
19. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.
Huang M; Lin Y; Wang C; Deng L; Chen M; Assaraf YG; Chen ZS; Ye W; Zhang D
Drug Resist Updat; 2022 Sep; 64():100849. PubMed ID: 35842983
[TBL] [Abstract][Full Text] [Related]
20. Clinical approaches toward tumor angiogenesis: past, present and future.
Fujita Y; Abe R; Shimizu H
Curr Pharm Des; 2008; 14(36):3820-34. PubMed ID: 19128235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]